Joe Zein, MD, PhD, discusses what to expect from his talk on sex differences in asthma at this year's American Thoracic Society (ATS) meeting.
Joe Zein, MD, PhD, is a staff physician in the Department of Pulmonary Medicine at Cleveland Clinic. At this year's American Thoracic Society (ATS) annual conference, Zein will give a talk on sex differences in asthma across the lifespan.
Transcript
Can you introduce yourself and give a preview of your talk on sex differences in asthma across the lifespan, to be presented at this year's ATS meeting?
My name is Joe Zein, and I'm a MD, PhD. I work for the Cleveland Clinic. I'm a staff physician. My research is mostly on the role of gender and sex hormones and asthma severity. I will basically go over all the findings I have been working on for the last 5 years, and mainly to look at some epidemiological data, distribution of asthma severity as compared to just asthma prevalence, and also comparing men and women in terms of outcome with asthma, mainly mortality and severity and stuff like this.
What are you most looking forward to at the meeting?
I'm looking forward to actually have interactions with other scientists and other physicians, so I can exchange my opinions and also learn from them at the same time. I think the question section at the end is for me important so I can interact with other scientists and know how they think and exchange knowledge.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More